JP2023528341A5 - - Google Patents

Info

Publication number
JP2023528341A5
JP2023528341A5 JP2022572558A JP2022572558A JP2023528341A5 JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5 JP 2022572558 A JP2022572558 A JP 2022572558A JP 2022572558 A JP2022572558 A JP 2022572558A JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
administered
fusion polypeptide
domain variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034967 external-priority patent/WO2021247430A1/en
Publication of JP2023528341A publication Critical patent/JP2023528341A/ja
Publication of JP2023528341A5 publication Critical patent/JP2023528341A5/ja
Pending legal-status Critical Current

Links

JP2022572558A 2020-06-01 2021-05-28 低メチル化剤を含むがんを治療するための併用療法 Pending JP2023528341A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063033074P 2020-06-01 2020-06-01
US63/033,074 2020-06-01
US202063106285P 2020-10-27 2020-10-27
US63/106,285 2020-10-27
US202063109083P 2020-11-03 2020-11-03
US63/109,083 2020-11-03
US202063114959P 2020-11-17 2020-11-17
US63/114,959 2020-11-17
US202163145925P 2021-02-04 2021-02-04
US63/145,925 2021-02-04
PCT/US2021/034967 WO2021247430A1 (en) 2020-06-01 2021-05-28 Combination therapies comprising a hypomethylation agent for treating cancer

Publications (2)

Publication Number Publication Date
JP2023528341A JP2023528341A (ja) 2023-07-04
JP2023528341A5 true JP2023528341A5 (cg-RX-API-DMAC10.html) 2024-06-04

Family

ID=76808133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572558A Pending JP2023528341A (ja) 2020-06-01 2021-05-28 低メチル化剤を含むがんを治療するための併用療法

Country Status (10)

Country Link
US (1) US12343377B2 (cg-RX-API-DMAC10.html)
EP (1) EP4157315A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023528341A (cg-RX-API-DMAC10.html)
KR (1) KR20230018475A (cg-RX-API-DMAC10.html)
CN (1) CN115666620A (cg-RX-API-DMAC10.html)
AU (1) AU2021283083A1 (cg-RX-API-DMAC10.html)
CA (1) CA3178157A1 (cg-RX-API-DMAC10.html)
IL (1) IL298644A (cg-RX-API-DMAC10.html)
MX (1) MX2022014784A (cg-RX-API-DMAC10.html)
WO (1) WO2021247430A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术(上海)有限公司 一种新的重组双功能融合蛋白及其制备和应用
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
CA3141130A1 (en) * 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术(上海)有限公司 一种新的重组双功能融合蛋白及其制备和应用
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
WO2017177333A1 (en) 2016-04-15 2017-10-19 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
CN110300764A (zh) 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
CA3057718A1 (en) 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
JP2021534769A (ja) 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2023528341A (ja) 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Similar Documents

Publication Publication Date Title
JP2023503943A5 (cg-RX-API-DMAC10.html)
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
JP2019530434A5 (cg-RX-API-DMAC10.html)
JP7729778B2 (ja) Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体
US20230416402A1 (en) Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2
CN101868478B (zh) 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法
US20240076355A1 (en) Interferon Prodrugs and Methods of Making and Using the Same
JP2002514405A5 (cg-RX-API-DMAC10.html)
CA3173919A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
PT771216E (pt) Metodos e composicoes para a coagulacao especifica da vasculatura tumoral
CN106536562A (zh) 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合,和其用途
JP2007500236A5 (cg-RX-API-DMAC10.html)
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2024520902A5 (cg-RX-API-DMAC10.html)
JP2019524713A5 (cg-RX-API-DMAC10.html)
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2022513421A5 (cg-RX-API-DMAC10.html)
JP2025523369A5 (cg-RX-API-DMAC10.html)
KR20230018475A (ko) 암 치료용 저메틸화제를 포함하는 병용 요법
JP2015529656A5 (cg-RX-API-DMAC10.html)
CN111936170A (zh) 降低抗cd30抗体药物缀合物疗法的副作用的方法
US20220185857A1 (en) Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JP2025511002A (ja) 活性化可能な二重特異性抗cd3および抗pd-l1タンパク質ならびにその使用